

Tamirisa N, et al. The Impact of Chemotherapy Sequence on Survival in Node-Positive Invasive Lobular Carcinoma

Supplemental Tables

**Supplemental Table 1.** Adjusted Overall Survival, cT1-4c, cN1-3 Invasive Lobular Carcinoma Patients, National Cancer Data Base, 2004-2013, Stage II (N=8,852)

**Supplemental Table 2.** Adjusted Overall Survival, cT1-4c, cN1-3 Invasive Lobular Carcinoma Patients, National Cancer Data Base, 2004-2013, Stage III (N=4,473)

**Supplemental Table 1. Adjusted Overall Survival, cT1-4c, cN1-3 Invasive Lobular Carcinoma Patients, National Cancer Data Base, 2004-2013, Stage II (N=8,852)**

	HR (95% CI)	P-Value	Overall P-Value
Treatment group			<0.001
ACT	REF		
NACT	1.39 (1.24 - 1.57)	<0.001	
Age (years)			<0.001
≥50	REF		
<50	0.63 (0.55 - 0.72)	<0.001	
Race			0.03
White	REF		
Black	1.22 (1.04 - 1.43)	0.01	
Other	0.84 (0.59 - 1.21)	0.36	
Ethnicity			<0.001
Hispanic	REF		
Non-Hispanic	1.73 (1.29 - 2.31)	<0.001	
Charlson/Deyo comorbidity score			<0.001
0	REF		
1	1.34 (1.15 - 1.57)	<0.001	
≥2	1.62 (1.19 - 2.21)	0.002	
Clinical T stage			<0.001
1	REF		
2	1.39 (1.19 - 1.61)	<0.001	
3	1.73 (1.46 - 2.04)	<0.001	
Grade			<0.001
1	REF		
2	1.19 (1.01 - 1.39)	0.04	
3	1.79 (1.49 - 2.15)	<0.001	
Surgery type			0.57
Lumpectomy	REF		
Mastectomy	1.10 (0.79 - 1.55)	0.57	
Treated with radiation post-lumpectomy			0.08
No	REF		
Yes	0.73 (0.51 - 1.03)	0.08	
Treated with radiation post-mastectomy			0.005
No	REF		
Yes	1.21 (1.06 - 1.39)	0.005	
Treated with endocrine therapy			<0.001
No	REF		
Yes	0.73 (0.63 - 0.83)	<0.001	
Income level (\$)			0.57
<\$35,000	REF		
≥\$35,000	1.05 (0.89 - 1.22)	0.57	

	HR (95% CI)	P-Value	Overall P-Value
Insurance status			<0.001
Private	REF		
Government	1.67 (1.49 - 1.88)	<0.001	
Not Insured	1.62 (1.15 - 2.29)	0.006	
Education level			0.22
≤80% High School Graduation Rate	REF		
>80% High School Graduation Rate	0.92 (0.79 - 1.05)	0.22	
Facility type			0.29
Academic	REF		
Integrated Network	1.12 (0.91 - 1.38)	0.27	
Comprehensive	1.01 (0.88 - 1.16)	0.89	
Community	1.18 (0.96 - 1.44)	0.11	
Facility location			0.08
South	REF		
Midwest	1.03 (0.89 - 1.19)	0.68	
Northeast	0.91 (0.77 - 1.07)	0.25	
West	0.83 (0.69 - 0.99)	0.04	

Hazard ratios, confidence intervals, and p-values are from a Cox proportional hazards model, stratified by year of diagnosis (grouped as 2004-2009 and 2010-2013) and hormone receptor status (positive/negative). A robust sandwich covariance estimator was used to account for correlation of patients treated at the same facility.

ACT: adjuvant chemotherapy. NACT: neoadjuvant chemotherapy.

**Supplemental Table 2. Adjusted Overall Survival, cT1-4c, cN1-3 Invasive Lobular Carcinoma Patients, National Cancer Data Base, 2004-2013, Stage III (N=4,473)**

	HR (95% CI)	P-Value	Overall P-Value
Treatment group			<0.001
ACT	REF		
NACT	1.36 (1.16 - 1.59)	<0.001	
Age (years)			0.35
≥50	REF		
<50	0.93 (0.79 - 1.09)	0.35	
Race			0.001
White	REF		
Black	1.23 (1.00 - 1.52)	0.046	
Other	0.48 (0.29 - 0.79)	0.004	
Ethnicity			0.41
Hispanic	REF		
Non-Hispanic	1.15 (0.83 - 1.58)	0.41	
Charlson/Deyo comorbidity score			0.22
0	REF		
1	1.15 (0.96 - 1.38)	0.14	
≥2	1.24 (0.83 - 1.84)	0.29	
Clinical T stage			<0.001
1	REF		
2	1.01 (0.79 - 1.28)	0.96	
3	1.12 (0.89 - 1.41)	0.35	
4	1.92 (1.43 - 2.58)	<0.001	
Clinical N stage			<0.001
1	REF		
2	1.26 (0.97 - 1.65)	0.09	
3	2.06 (1.58 - 2.68)	<0.001	
Grade			<0.001
1	REF		
2	1.31 (1.06 - 1.62)	0.01	
3	1.59 (1.26 - 2.01)	<0.001	
Surgery type			0.99
Lumpectomy	REF		
Mastectomy	0.99 (0.69 - 1.43)	0.99	
Treated with radiation post-lumpectomy			0.009
No	REF		
Yes	0.58 (0.39 - 0.87)	0.009	
Treated with radiation post-mastectomy			<0.001
No	REF		
Yes	0.73 (0.61 - 0.86)	<0.001	
Treated with endocrine therapy			0.006

	HR (95% CI)	P-Value	Overall P-Value
No	REF		
Yes	0.79 (0.67 - 0.93)	0.006	
Income level (\$)			0.34
<\$35,000	REF		
≥\$35,000	0.92 (0.77 - 1.09)	0.34	
Insurance status			<0.001
Private	REF		
Government	1.39 (1.22 - 1.59)	<0.001	
Not Insured	0.78 (0.48 - 1.27)	0.32	
Education level			0.13
≤80% High School Graduation Rate	REF		
>80% High School Graduation Rate	0.88 (0.75 - 1.04)	0.13	
Facility type			0.041
Academic	REF		
Integrated Network	1.16 (0.90 - 1.48)	0.25	
Comprehensive	1.27 (1.07 - 1.49)	0.01	
Community	1.24 (0.98 - 1.56)	0.07	
Facility location			0.004
South	REF		
Midwest	1.15 (0.96 - 1.37)	0.14	
Northeast	0.91 (0.76 - 1.09)	0.32	
West	0.78 (0.63 - 0.95)	0.02	

Hazard ratios, confidence intervals, and p-values are from a Cox proportional hazards model, stratified by year of diagnosis (grouped as 2004-2009 and 2010-2013) and hormone receptor status (positive/negative). A robust sandwich covariance estimator was used to account for correlation of patients treated at the same facility.

ACT: adjuvant chemotherapy. NACT: neoadjuvant chemotherapy.